** Shares of Alphamab Oncology 9966.HK drop 11.8% to HK$8.07, their biggest intraday pct decline since May 12
** Stock hits the lowest since May 21, and on course to snap three straight sessions of gains, if current trend holds
** Alphamab Oncology says controlling shareholder plans to sell 14.6 mln existing shares at HK$8.05 each in share placement, reducing its stake to 31% from 32.5%
** Co says the controlling shareholder will use the proceeds to repay existing personal liabilities and debts, and the placement is not expected to have any impact on its business or operations
** The Hang Seng Biotech Index .HSHKBIO gains 1.3% and the Hang Seng Index .HSI climbs 1.2%
** Alphamab stock up 133.7%, YTD
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.